版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Drugs that Affect the Cardiovascular System Electrophysiology Vaughn-Williams classification Antihypertensives Hemostatic agents Dependent upon Adequate amounts of ATP Adequate amounts of Ca+ Coordinated electrical stimulus Needed to: Maintain electrochemical gradients Propagate action potentials Po
2、wer muscle contraction Calcium is glue that links electrical and mechanical events. Heart capable of automaticity Two types of myocardial tissue Contractile Conductive Impulses travel through action potential superhighway. Sinoatrial node Atrioventricular node Bundle of His Bundle Branches Fascicles
3、 Purkinje Network Two types of action potentials Fast potentials Found in contractile tissue Slow potentials Found in SA, AV node tissues -80 -60 -40 -20 0 +20 RMP -80 to 90 mV Phase 1 Phase 2 Phase 3 Phase 4 controlled by Na+ channels = “fast channels” Phase 0: Na+ influx “fast sodium channels” Pha
4、se 1: K + efflux Phase 2: (Plateau) K + efflux AND Ca + + influx Phase 3: K+ efflux Phase 4: Resting Membrane Potential -80 -60 -40 -20 0 Phase 4Phase 3 dependent upon Ca+ channels = “slow channels” Self-depolarizing Responsible for automaticity Phase 4 depolarization slow sodium-calcium channels le
5、aky to sodium Phase 3 repolarization K+ efflux Intrinsic firing rates: SA = 60 100 AV = 45 60 Purkinje = 15 - 45 SA is primary Faster depolarization rate Faster Ca+ leak Others are backups Graduated depolarization rate Graduated Ca+ leak rate APD ERP RRPrelative refractory period effective refractor
6、y period action potential duration Abnormal genesis Imbalance of ANS stimuli Pathologic phase 4 depolarization Ectopic foci Abnormal conduction Analogies: One way valve Buggies stuck in muddy roads All antidysrhythmics have arrythmogenic properties In other words, they all can CAUSE dysrhythmias too
7、! Describes weight of supporting evidence NOT mechanism Class I Class IIa Class IIb Indeterminant Class III View AHA definitions Class 1 Ia Ib Ic Class II Class III Class IV Misc Description of mechanism NOT evidence Decrease Na+ movement in phases 0 and 4 Decreases rate of propagation (conduction)
8、via tissue with fast potential (Purkinje) Ignores those with slow potential (SA/AV) Indications: ventricular dysrhythmias Slow conduction through ventricles Decrease repolarization rate Widen QRS and QT intervals May promote Torsades des Pointes! PDQ: procainamide (Pronestyl) disopyramide (Norpace)
9、qunidine (Quinidex) Slow conduction through ventricles Increase rate of repolarization Reduce automaticity Effective for ectopic foci May have other uses LTMD: lidocaine (Xylocaine) tocainide (Tonocard) mexiletine (Mexitil) phenytoin (Dilantin) Slow conduction through ventricles, atria & conduction
10、system Decrease repolarization rate Decrease contractility Rare last chance drug flecainide (Tambocor) propafenone (Rythmol) Beta1 receptors in heart attached to Ca+ channels Gradual Ca+ influx responsible for automaticity Beta1 blockade decreases Ca+ influx Effects similar to Class IV (Ca+ channel
11、blockers) Limited # approved for tachycardias propranolol (Inderal) acebutolol (Sectral) esmolol (Brevibloc) Decreases K+ efflux during repolarization Prolongs repolarization Extends effective refractory period Prototype: bretyllium tosylate (Bretylol) Initial norepi discharge may cause temporary hy
12、pertension/tachycardia Subsequent norepi depletion may cause hypotension Similar effect as blockers Decrease SA/AV automaticity Decrease AV conductivity Useful in breaking reentrant circuit Prime side effect: hypotension & bradycardia verapamil (Calan) diltiazem (Cardizem) Note: nifedipine doesnt wo
13、rk on heart adenosine (Adenocard) Decreases Ca+ influx & increases K+ efflux via 2nd messenger pathway Hyperpolarization of membrane Decreased conduction velocity via slow potentials No effect on fast potentials Profound side effects possible (but short- lived) Cardiac Glycocides digoxin (Lanoxin) I
14、nhibits NaKATP pump Increases intracellular Ca+ via Na+-Ca+ exchange pump Increases contractility Decreases AV conduction velocity Antihypertensives diuretics beta blockers angiotensin-converting enzyme (ACE) inhibitors calcium channel blockers vasodilators Cardiac Output = SV x HR PVR = Afterload K
15、ey: CCB = calcium channel blockers CA Adrenergics = central-acting adrenergics ACEis = angiotensin-converting enzyme inhibitors cardiac factorscirculating volume heart rate contractility 1. Beta Blockers 2. CCBs 3. C.A. Adrenergics salt aldosterone ACEis Diuretics BP = CO x PVR Hormones 1. vasodilat
16、ors 2. ACEIs 3. CCBs Central Nervous System 1. CA Adrenergics Peripheral Sympathetic Receptors alpha beta 1. alpha blockers 2. beta blockers Local Acting 1. Peripheral-Acting Adrenergics Stimulate alpha1 receptors - hypertension Block alpha1 receptors - hypotension doxazosin (Cardura) prazosin (Mini
17、press) terazosin (Hytrin) Stimulate alpha2 receptors inhibit alpha1 stimulation hypotension clonidine (Catapress) methyldopa (Aldomet) reserpine (Serpalan) inhibits the release of NE diminishes NE stores leads to hypotension Prominent side effect of depression also diminishes seratonin Common dry mo
18、uth, drowsiness, sedation & constipation orthostatic hypotension Less common headache, sleep disturbances, nausea, rash & palpitations Angiotensin I ACE Angiotensin II 1. potent vasoconstrictor - increases BP 2. stimulates Aldosterone - Na+ & H2O reabsorbtion . RAAS Angiotensin II = vasoconstrictor
19、Constricts blood vessels & increases BP Increases SVR or afterload ACE-I blocks these effects decreasing SVR & afterload Aldosterone secreted from adrenal glands cause sodium & water reabsorption Increase blood volume Increase preload ACE-I blocks this and decreases preload captopril (Capoten) enala
20、pril (Vasotec) lisinopril (Prinivil & Zestril) quinapril (Accupril) ramipril (Altace) benazepril (Lotensin) fosinopril (Monopril) Used for: Angina Tachycardias Hypertension diltiazem & verapamil nifedipine (and other dihydropyridines) diltiazem & verapamil decrease automaticity & conduction in SA &
21、AV nodes decrease myocardial contractility decreased smooth muscle tone decreased PVR nifedipine decreased smooth muscle tone decreased PVR Cardiovascular hypotension, palpitations & tachycardia Gastrointestinal constipation & nausea Other rash, flushing & peripheral edema diltiazem (Cardizem) verap
22、amil (Calan, Isoptin) nifedipine (Procardia, Adalat) . loop of Henle proximal tubule Distal tubule Collecting duct Water follows Na+ 20-25% of all Na+ is reabsorbed into the blood stream in the loop of Henle 5-10% in distal tubule & 3% in collecting ducts If it can not be absorbed it is excreted wit
23、h the urine Blood volume = preload ! electrolyte losses Na+ & K+ fluid losses dehydration myalgia N/V/D dizziness hyperglycemia Thiazides: chlorothiazide (Diuril) & hydrochlorothiazide (HCTZ, HydroDIURIL) Loop Diuretics furosemide (Lasix), bumetanide (Bumex) Potassium Sparing Diuretics spironolacton
24、e (Aldactone) Directly relaxes arteriole smooth muscle Decrease SVR = decrease afterload hydralazine (Apresoline) Reflex tachycardia sodium nitroprusside (Nipride) Cyanide toxicity in renal failure CNS toxicity = agitation, hallucinations, etc. diazoxide Hyperstat hydralazine Apresoline minoxidil Lo
25、niten sodium Nitroprusside Nipride Drugs Affecting Hemostasis Reproduce figure 11-9, page 359 Sherwood Reproduce following components of cascade: Prothrombin - thrombin Fibrinogen - fibrin Plasminogen - plasmin Inhibit the aggregation of platelets Indicated in progressing MI, TIA/CVA Side Effects: u
26、ncontrolled bleeding No effect on existing thrombi Inhibits COX Arachidonic acid (COX) - TXA2 ( aggregation) Fibrinogen abciximab (ReoPro) eptifibitide (Integrilin) tirofiban (Aggrastat) Interrupt clotting cascade at various points No effect on platelets Heparin & LMW Heparin (Lovenox) warfarin (Cou
27、madin) Endogenous Released from mast cells/basophils Binds with antithrombin III Antithrombin III binds with and inactivates excess thrombin to regionalize clotting activity. Most thrombin (80-95%) captured in fibrin mesh. Antithrombin-heparin complex 1000X as effective as antithrombin III alone Mea
28、sured in Units, not milligrams Indications: MI, PE, DVT, ischemic CVA Antidote for heparin OD: protamine. MOA: heparin is strongly negatively charged. Protamine is strongly positively charged. Factors II, VII, IX and X all vitamin K dependent enzymes Warfarin competes with vitamin K in the synthesis
29、 of these enzymes. Depletes the reserves of clotting factors. Delayed onset (12 hours) due to existing factors Directly break up clots Promote natural thrombolysis Enhance activation of plasminogen Time is Muscle streptokinase (Streptase) alteplase (tPA, Activase) anistreplase (Eminase) reteplase (R
30、etevase) tenecteplase (TNKase) Cholesterol important component in membranes and as hormone precursor Synthesized in liver Hydroxymethylglutaryl coenzyme A reductase (HMG CoA reductase) dependant Stored in tissues for latter use Insoluble in plasma (a type of lipid) Must have transport mechanism Lipid
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026年可信数据空间建设与行业数据集流通交易
- 2026年核能领域专精特新企业培育与成长路径
- 2026年水产冻品仓单贷盘活存货资产全流程实务
- 2026年高镍正极材料循环寿命提升关键技术研究
- 2026年群体智能系统分布式协同优化收敛性与多样性平衡难题
- 2026年生物基材料纳入生物制造未来产业战略布局指南
- 2026年关键矿产资源在eVTOL电池中的应用
- 2026年融资平台存量经营性金融债务压降62%后续攻坚方案
- 2026湖南娄底市人力资源和社会保障局娄底市就业见习岗位备考题库及完整答案详解【全优】
- 2026江苏镇江市润州区卫生健康系统事业单位招聘专业技术人员21人备考题库附参考答案详解(培优b卷)
- 老年2型糖尿病合并认知障碍照护方案
- 中医门诊病历书写规范模板
- 2025年医保培训试题(答案+解析)
- 八大特殊作业危险源识别及评价表
- 【生物】江苏省南通市2024-2025学年高一下学期6月期末试题(解析版)
- 个人山林承包合同
- 山东德州2010-2022年中考满分作文63篇
- 外派员工绩效考核管理制度范例
- 机械加工产品溯源方案(3篇)
- 江苏省苏锡常镇2025届高三下学期一模考试英语试题(解析版)
- 人寿保险面试题及答案
评论
0/150
提交评论